Pharma innovative research boosted with gut and gut-brain axis
Make major scientific breakthrough in your Pharma innovative research
Thanks to this holistic approach rooted in the gut and gut-brain axis, we accompany your innovation process, design and implement experimental protocols adapted to your pharmaceutical pipeline development objectives. To do this, we offer a wide range of tests using our expertise to provide you with real differentiation opportunities:
- Screening of potential assets
- Improvement of leads profiling and selection
- Comparison of various drug candidates in different organs
- Characterization and consolidation of the therapeutic effects
- Characterization and consolidation the mechanism of action
- Repositioning of your compound
Reveal your pharmaceutical leads potential thanks to the gut and gut-organs axis!
New legislation, patent expiration and rising healthcare costs are demanding decisive changes in the global pharmaceutical industry.
You evolve in a very competitive environment, and you need a new and disruptive approach to respond to a more global medicine integrating the digestive sphere and its impacts on the related peripheral organs.
Gut and gut-organs preclinical studies give you a great boost for the development of your molecules
Enterosys is a CRO rooted in gut for Pharma innovative research
Enterosys offers rapid and innovative protocols for the analysis of physiological parameters in real time. Our approaches save time and costs in the development of your therapeutics to quickly position or reposition your assets. We help researchers advance science towards precision health much faster.
Our holistic gut-organs approach demonstrates the beneficial effects of molecules of interest and may also detect potential side effects on other organs very early in the development process. Our cutting-edge know-how makes the best of your molecule and de-risk your innovation.
Our resources about intestinal scientific wealth
The enteric nervous system (ENS) plays a key role in controlling the gut-brain axis under normal and pathological conditions, such as type 2 diabetes. The discovery of intestinal actors, such as enterosynes, able to modulate the ENS-induced duodenal contraction is considered a pioneering approach.
In addition to their classical mode of action in the brain, circulating factors may modulate the release of reactive oxygen/nitrogen species (ROS/RNS) from endothelial cells that compose the blood-brain-barrier without entering the brain. Due to their high capacity to diffuse across membranes, ROS/RNS can reach neurons and modify their activity. This study investigates other mechanisms of actions in which beta-blockers may display a central effect without crossing the blood brain barrier.
Targeting the Enteric Nervous System to Treat Metabolic Disorders? “Enterosynes” as Therapeutic Gut Factors
The gut-brain axis is of crucial importance for controlling glucose homeostasis. Alteration of this axis promotes the type 2 diabetes phenotype. Recently, a new concept has emerged to demonstrate the crucial role of the enteric nervous system in the control of glycaemia via the hypothalamus.